Kathleen N Moore1, James J Java2, Katrina N Slaughter3, Peter G Rose4, Rachelle Lanciano5, Paul A DiSilvestro6, J Tate Thigpen7, Yi-Chun Lee8, Krishnansu S Tewari9, Junzo Chino10, Shelly M Seward11, David S Miller12, Ritu Salani13, David H Moore14, Frederick B Stehman15. 1. Division of Gynecologic Oncology, Stephenson Oklahoma Cancer Center at the University of Oklahoma, 800 NE 10th Street, Oklahoma City, OK 73121, United States. Electronic address: kathleen-moore@ouhsc.edu. 2. NRG Oncology Statistics & Data Management Center, Roswell Park Cancer Institute, Buffalo, NY 14263, United States. Electronic address: james.j.java@gmail.com. 3. Division of Gynecologic Oncology, Ochsner Medical Center, 1514 Jefferson Hwy, New Orleans, LA 70121, United States. Electronic address: katrina-slaughter@ouhsc.edu. 4. Division of Gynecologic Oncology, Cleveland Clinic Foundation, Cleveland, OH 44109, United States. Electronic address: rosep@ccf.org. 5. Dept. of Radiation Oncology, Crozer Keystone Regional Cancer Center at Broomall, Crozer Keystone Health System, Broomall, PA 19008, United States. Electronic address: rlancmd@gmail.com. 6. Division of Gynecologic Oncology, Women & Infants Hospital, Providence, RI 02905, United States. Electronic address: pdisilvestro@wihri.org. 7. Division of Medical Oncology, University of Mississippi Medical Center, Jackson, MS 39216, United States. Electronic address: jtthigpen@att.net. 8. Division of Gynecologic Oncology, State University of New York Downstate, Brooklyn, NY 11203, United States. Electronic address: yi-chun.lee@downstate.edu. 9. Division of Gynecologic Oncology, University of California at Irvine, Orange, CA 92868, United States. Electronic address: ktewari@uci.edu. 10. Radiation Oncology, Duke University Medical Center, Durham, NC 27710, United States. Electronic address: junzo.chino@duke.edu. 11. Division of Gynecologic Oncology, Wayne State University/Karmanos Cancer Center, Detroit, MI 48201, United States. Electronic address: sseward@med.wayne.edu. 12. Division of Gynecologic Oncology, UT Southwestern Medical Center at Dallas, Dallas, TX 75390, United States. Electronic address: David.Miller@utsouthwestern.edu. 13. Division of Gynecologic Oncology, Ohio State University Medical Center, Columbus, OH 43210, United States. Electronic address: ritu.salani@osumc.edu. 14. Division of Obstetrics & Gynecology, Franciscan St. Francis Health, Indianapolis, IN 46237, United States. Electronic address: David.Moore@franciscanalliance.org. 15. Division of Gynecologic Oncology, Indiana University School of Medicine, Mel and Bren Simon Cancer Center, Indianapolis, IN 46202, United States. Electronic address: fstehman@iupui.edu.
Abstract
OBJECTIVE: To determine the effect of age on completion of and toxicities following treatment of local regionally advanced cervical cancer (LACC) on Gynecologic Oncology Group (GOG) Phase I-III trials. METHODS: An ancillary data analysis of GOG protocols 113, 120, 165, 219 data was performed. Wilcoxon, Pearson, and Kruskal-Wallis tests were used for univariate and multivariate analysis. Log rank tests were used to compare survival lengths. RESULTS: One-thousand-three-hundred-nineteen women were included; 60.7% were Caucasian, 15% were age 60-70years and an additional 5% were >70; 87% had squamous histology, 55% had stage IIB disease and 34% had IIIB disease. Performance status declined with age (p=0.006). Histology and tumor stage did not significantly differ. Number of cycles of chemotherapy received, radiation treatment time, nor dose modifications varied with age. Notably, radiation protocol deviations and failure to complete brachytherapy (BT) did increase with age (p=0.022 and p<0.001 respectively). Only all grade lymphatic (p=0.006) and grade≥3 cardiovascular toxicities (p=0.019) were found to vary with age. A 2% increase in the risk of death for every year increase >50 for all-cause mortality (HR 1.02; 95% CI, 1.01-1.04) was found, but no association between age and disease specific mortality was found. CONCLUSION: This represents a large analysis of patients treated for LACC with chemo/radiation, approximately 20% of whom were >60years of age. Older patients, had higher rates of incomplete brachytherapy which is not explained by collected toxicity data. Age did not adversely impact completion of chemotherapy and radiation or toxicities.
OBJECTIVE: To determine the effect of age on completion of and toxicities following treatment of local regionally advanced cervical cancer (LACC) on Gynecologic Oncology Group (GOG) Phase I-III trials. METHODS: An ancillary data analysis of GOG protocols 113, 120, 165, 219 data was performed. Wilcoxon, Pearson, and Kruskal-Wallis tests were used for univariate and multivariate analysis. Log rank tests were used to compare survival lengths. RESULTS: One-thousand-three-hundred-nineteen women were included; 60.7% were Caucasian, 15% were age 60-70years and an additional 5% were >70; 87% had squamous histology, 55% had stage IIB disease and 34% had IIIB disease. Performance status declined with age (p=0.006). Histology and tumor stage did not significantly differ. Number of cycles of chemotherapy received, radiation treatment time, nor dose modifications varied with age. Notably, radiation protocol deviations and failure to complete brachytherapy (BT) did increase with age (p=0.022 and p<0.001 respectively). Only all grade lymphatic (p=0.006) and grade≥3 cardiovascular toxicities (p=0.019) were found to vary with age. A 2% increase in the risk of death for every year increase >50 for all-cause mortality (HR 1.02; 95% CI, 1.01-1.04) was found, but no association between age and disease specific mortality was found. CONCLUSION: This represents a large analysis of patients treated for LACC with chemo/radiation, approximately 20% of whom were >60years of age. Older patients, had higher rates of incomplete brachytherapy which is not explained by collected toxicity data. Age did not adversely impact completion of chemotherapy and radiation or toxicities.
Authors: Candace S Sheppard; Mariam El-Zein; Agnihotram V Ramanakumar; Alex Ferenczy; Eduardo L Franco Journal: Int J Cancer Date: 2016-01-29 Impact factor: 7.396
Authors: T Pignon; J C Horiot; M Bolla; H van Poppel; H Bartelink; F Roelofsen; F Pene; A Gerard; N Einhorn; T D Nguyen; M Vanglabbeke; P Scalliet Journal: Radiother Oncol Date: 1997-02 Impact factor: 6.280
Authors: Charu Sharma; Israel Deutsch; David P Horowitz; Dawn L Hershman; Sharyn N Lewin; Yu-Shiang Lu; Alfred I Neugut; Thomas J Herzog; Clifford K Chao; Jason D Wright Journal: Cancer Date: 2011-10-28 Impact factor: 6.860
Authors: P G Rose; B N Bundy; E B Watkins; J T Thigpen; G Deppe; M A Maiman; D L Clarke-Pearson; S Insalaco Journal: N Engl J Med Date: 1999-04-15 Impact factor: 91.245
Authors: Inacelli Queiroz de Souza Caires; Karla Teixeira Souza; Marcelo Vailati Negrão; Julia Andrade de Oliveira; Romualdo Barroso-Sousa; Rafael Caires Alvino de Lima; Paulo Marcelo Gehm Hoff; Maria del Pilar Estevez Diz Journal: Eur J Obstet Gynecol Reprod Biol Date: 2015-06-20 Impact factor: 2.435
Authors: Paul A DiSilvestro; Shamshad Ali; Peter S Craighead; Joseph A Lucci; Yi-Chun Lee; David E Cohn; Nicola M Spirtos; Krishnasu S Tewari; Carolyn Muller; Walter H Gajewski; Margaret M Steinhoff; Bradley J Monk Journal: J Clin Oncol Date: 2014-01-06 Impact factor: 44.544
Authors: Rachelle Lanciano; Alison Calkins; Brian N Bundy; Groesbeck Parham; Joseph A Lucci; David H Moore; Bradley J Monk; Dennis M O'Connor Journal: J Clin Oncol Date: 2005-10-17 Impact factor: 44.544
Authors: Charles Kunos; Chunqiao Tian; Steven Waggoner; Peter G Rose; Rachelle Lanciano Journal: Int J Gynecol Cancer Date: 2009-10 Impact factor: 3.437
Authors: Dana Chase; Helen Q Huang; Bradley J Monk; Lois Michelle Ramondetta; Richard T Penson; Karen Gil; Lisa M Landrum; Mario Leitao; Ana Oaknin; Warner K Huh; Heather L Pulaski; Katina Robison; Saketh R Guntupalli; Debra Richardson; Ritu Salani; Michael W Sill; Lari B Wenzel; Krishnansu Sujata Tewari Journal: Int J Gynecol Cancer Date: 2020-02-28 Impact factor: 3.437
Authors: Taylor R Cushman; Waqar Haque; Hari Menon; Chad G Rusthoven; E Brian Butler; Bin S Teh; Vivek Verma Journal: J Gynecol Oncol Date: 2018-11 Impact factor: 4.401